We would love to hear your thoughts about our site and services, please take our survey here.
In perspective - It is not EBOLA!
https://www.statnews.com/2021/12/04/omicron-covid19-south-africa-data/
As the world waits for studies that give a clear picture of the Omicron variant, early clinical data emerging from South Africa hint at a virus that may cause less severe cases of Covid-19.
The South African Medical Research Council posted a report Saturday of the early experiences at several hospitals in Gauteng Province, where Omicron was first spotted in the country. Strikingly, most hospitalized patients who tested positive for Covid did not need supplemental oxygen. Few developed Covid pneumonia, few required high-level care, and fewer still were admitted to intensive care.
Experts caution against reading too much into these early reports, which are based on small numbers of patients. They suggest it will take time for the true profile of the Omicron variant to come into focus. But several note that while early discussions about previous variants of concern have hinged on trying to figure out whether they caused more severe disease, with Omicron the questions relate to whether it is associated with milder infections.
The report included an analysis of 42 Covid patients in the hospital on Dec. 2 which showed that most were actually hospitalized for other medical reasons; their infections were only detected because hospitals are testing all incoming patients for Covid. Many did not have respiratory symptoms. And the average length of hospital stay was 2.8 days, far shorter than the average of 8.5 days recorded in the region over the past 18 months, the report said.
The relatively low number of Covid-19 pneumonia hospitalizations in the general, high care and ICU wards constitutes a very different picture compared to the beginning of previous waves,” said the report, authored by Fareed Abdullah, director of the SAMRC’s office of AIDS and TB research.
Michael Osterholm, director of the University of Minnesota’s Center for Infectious Diseases Research and Policy, told STAT he has “really been impressed by the relative lack of severe illness” seen with Omicron so far. “We’re just not seeing the number of patients that have been seen in previous surges who are seriously ill, even this soon into the surge.”
Amesh Adalja, an expert on emerging infectious disease and pandemic preparedness at Johns Hopkins University’s Center for Health Security, said more data are needed but the early indications are “very intriguing.”
“It’s part of a trend of anecdotal reports that we’re hearing that the clinical spectrum seems to be more mild, especially in vaccinated people,” he said.
Just sharing ... hope all is well fellas.
It is not EBOLA!
AND WW3/ hypersonic missiles is probably a greater danger than Covid ... lets put things in perspective, does tourism END? Yes OR No ... this too shall pass.
_____________________________
https://www.statnews.com/2021/12/04/omicron-covid19-south-africa-data/
As the world waits for studies that give a clear picture of the Omicron variant, early clinical data emerging from South Africa hint at a virus that may cause less severe cases of Covid-19.
The South African Medical Research Council posted a report Saturday of the early experiences at several hospitals in Gauteng Province, where Omicron was first spotted in the country. Strikingly, most hospitalized patients who tested positive for Covid did not need supplemental oxygen. Few developed Covid pneumonia, few required high-level care, and fewer still were admitted to intensive care.
Experts caution against reading too much into these early reports, which are based on small numbers of patients. They suggest it will take time for the true profile of the Omicron variant to come into focus. But several note that while early discussions about previous variants of concern have hinged on trying to figure out whether they caused more severe disease, with Omicron the questions relate to whether it is associated with milder infections.
The report included an analysis of 42 Covid patients in the hospital on Dec. 2 which showed that most were actually hospitalized for other medical reasons; their infections were only detected because hospitals are testing all incoming patients for Covid. Many did not have respiratory symptoms. And the average length of hospital stay was 2.8 days, far shorter than the average of 8.5 days recorded in the region over the past 18 months, the report said.
The relatively low number of Covid-19 pneumonia hospitalizations in the general, high care and ICU wards constitutes a very different picture compared to the beginning of previous waves,” said the report, authored by Fareed Abdullah, director of the SAMRC’s office of AIDS and TB research.
Michael Osterholm, director of the University of Minnesota’s Center for Infectious Diseases Research and Policy, told STAT he has “really been impressed by the relative lack of severe illness” seen with Omicron so far. “We’re just not seeing the number of patients that have been seen in previous surges who are seriously ill, even this soon into the surge.”
Amesh Adalja, an expert on emerging infectious disease and pandemic preparedness at Johns Hopkins University’s Center for Health Security, said more data are needed but the early indications are “very intriguing.”
“It’s part of a trend of anecdotal reports that we’re hearing that the clinical spectrum seems to be more mild, especially in vaccinated people,” he said
In perspective - It is not EBOLA!
https://www.statnews.com/2021/12/04/omicron-covid19-south-africa-data/
As the world waits for studies that give a clear picture of the Omicron variant, early clinical data emerging from South Africa hint at a virus that may cause less severe cases of Covid-19.
The South African Medical Research Council posted a report Saturday of the early experiences at several hospitals in Gauteng Province, where Omicron was first spotted in the country. Strikingly, most hospitalized patients who tested positive for Covid did not need supplemental oxygen. Few developed Covid pneumonia, few required high-level care, and fewer still were admitted to intensive care.
Experts caution against reading too much into these early reports, which are based on small numbers of patients. They suggest it will take time for the true profile of the Omicron variant to come into focus. But several note that while early discussions about previous variants of concern have hinged on trying to figure out whether they caused more severe disease, with Omicron the questions relate to whether it is associated with milder infections.
The report included an analysis of 42 Covid patients in the hospital on Dec. 2 which showed that most were actually hospitalized for other medical reasons; their infections were only detected because hospitals are testing all incoming patients for Covid. Many did not have respiratory symptoms. And the average length of hospital stay was 2.8 days, far shorter than the average of 8.5 days recorded in the region over the past 18 months, the report said.
The relatively low number of Covid-19 pneumonia hospitalizations in the general, high care and ICU wards constitutes a very different picture compared to the beginning of previous waves,” said the report, authored by Fareed Abdullah, director of the SAMRC’s office of AIDS and TB research.
Michael Osterholm, director of the University of Minnesota’s Center for Infectious Diseases Research and Policy, told STAT he has “really been impressed by the relative lack of severe illness” seen with Omicron so far. “We’re just not seeing the number of patients that have been seen in previous surges who are seriously ill, even this soon into the surge.”
Amesh Adalja, an expert on emerging infectious disease and pandemic preparedness at Johns Hopkins University’s Center for Health Security, said more data are needed but the early indications are “very intriguing.”
“It’s part of a trend of anecdotal reports that we’re hearing that the clinical spectrum seems to be more mild, especially in vaccinated people,” he said.
Where are the Nightingale Hospitals? Were they ever used?
This is not Covid day 1, we are in a better position whatever the headlines might suggest. The media wants to create fear, and doom, as that gets clicks.
The issue we have is Government getting in the way of allowing the Private sector to move forward and if need be to evolve to the landscape.
The constant moving of goal posts is just shooting yourself in the foot.
IF this new strain is more infectious and milder - good. Let it take over the Delta Variant, and lets get on with our lifes.
Lockdowns are expensive, and a misuse of state capital ... doing the same thing over and over again and expecting different outcomes as we know is insane.
The situation is more political than anything else.
We are at a greater danger of WW3 than anything Covid related imo. It wasn't that long ago the testing measures changed, when was the supposed freedom day, June, July?
We are well versed in how this plays out we have been through it before when it was a complete unknown. It is no longer an unknown.
This too shall pass.
All the best.
I've worked in asset management since I left uni in 08, house brokers etc, uts about creating trade flow, but we use our in-house forecasts when communi action narrative and views to clients, whether that be a client invested in a global al equity mandate where we have holdings that are covered by the investment bank or if we are advising clients on direct basis. Analysts like economists
... some good some not so good, end of the day if you pick a Co.pany with good fundamentals and management t and a bit of time, it tends to produce a decent ROE.
Just my 2 cents.
that would have been my thoughts also, as someone bought early in the day before me on here and was 1078 I think, I would have expected my order to have moved up higher on the range, if that many orders had already been processed.
It will be interesting to see the product.
I personally feel its just manipulation at these levels, I think the company is focused on delivering what they normally do, and growing the business and addressing the image of the company via the previous labour issues.
With the shorting, inflation, Omicron ... its providing an opportunity to get into a company with a lot of potential at a cheap level.
Load the boat and leave it in the portfolio for medium, long term for me.
Shore capital, who have pretty much been bearish, came in at the start of November with their BUY recommendation ... so if even they see fair value in taking a long position at these levels, at some point the market will catch up.
Just my 2 cents for a Saturday.
Be well.
I think mine was 1090
pound cost averaging I suppose, if you have 50k to add, and you add in tranches of 10k ... if you are perhaps concerned about volatility, and entry price, but its not necessarily about timing the market, but time in the market per se ... that being told, use of TA can support entry ...
end of the day typical holding term for an investor, even at my work - we look at a minimum of 5 year term so you can ride out fluctuations, hence time in the market is core rather than timing as per our house view.
Horses for courses I suppose.
Some head winds, hence the discount ... ESG piece, which may stop some big funds from stepping back in until they feel confident that Labor practices have changed, inflationary pressures on margin, money is being spent on expansion and diversification towards different demographics and target markets. BOO uses social media and influencers like no one else, they really are good at marketing what is relatively cheap products and making them trendy, and on-point. The opening of the Centre in Manchester yesterday is a huge moment, I think it will be the place to be seen essentially, and they will be able to target higher margins and more niche upmarket products to clientele through a wider product offering.
Amazon also spending a huge sum on expanding distribution logistics, so they are looking to expand their control over the supply chain.
Even at the softer end of that framework, seeing Amazon delivery Vans on the roads ... with those individuals now wearing a Uniform.
Margins might well be compressed, I think once Xmas is out of the way many retailers might opt to push these costs onto the end consumer, its all relative ... IF Primark goes up 4%, and Boo go up 4%, no real difference.
The Business has been on expansion, should see some diversification via the Debenhams position also.
The market is pricing in as though the company is going broke imo.
Just my 2 cents for what its worth.
Took a position here.
Quite incredible really, at the depths of COVID March 2020/ 1.80, 1.90 and here we are today, back trading at 2018 levels.
Market completely discounting the progress the business has made, by a short attack it seems given the constant downward pressure.
Happy to add a bit more should it reach 1.50 level. It is a gift.
ATB.
I would agree with Oils and Digestibles, i'd want natural CBD, not Lab per se, however like anything ...
Why do you pay GBP 450 for a Balenciaga Tee when its of similar quality as a SuperDry Tee, but simply has a different logo.
People are crazy. You pay for a label if it represents niche, status, on trend.
I've ordered some of the products from the site, see what they are like.
One of my friends, who worked at McKinsey as a Pharma Consultant, just when she was starting out, and before she went into a meeting, the senior Director who was with her, told her to look expensive.
ATB.
imo ... pricing looks fine for the segment of the market they are targeting, evidently the actual quality of the product needs to be there.
Good feedback from that, reviews, word of mouth is then all you need.
The website imo, looks poor. Not to the standard I would expect if you are pricing at the levels suggested.
I buy decent face wash, skin creams etc anyway from https://www.cultbeauty.co.uk/.
Pricing isn't out of the realms of someone might pay now including the trendy CBD tag, ALBEIT, it has to actually be a good product.
I don't think .14 to .16 is out of the realms of possibility, run up, news, consolidation, then main event in February.
GLA
Not a clean indicator of trade flows I'm afraid mate.
Just looks at closest mid price, depending on spread you can make a buy look like a sell and vice versa.
SP down so sells must have been greater today.
.